Publicacións en colaboración con investigadores/as de KU Leuven (22)

2022

  1. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9

2020

  1. Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia

    Thrombosis Research, Vol. 195, pp. 139-145

  2. Performance of 18F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis

    Thrombosis Research, Vol. 194, pp. 153-157

2019

  1. Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis

    Thrombosis Research, Vol. 176, pp. 79-84

2017

  1. Screening for cancer in patients with unprovoked venous thromboembolism: Protocol for a systematic review and individual patient data meta-analysis

    BMJ Open, Vol. 7, Núm. 6

  2. Screening for occult cancer in patients with unprovoked venous thromboembolism

    Annals of Internal Medicine, Vol. 167, Núm. 6, pp. 410-417

2015

  1. Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia

    FASEB Journal, Vol. 29, Núm. 3, pp. 960-972

2014

  1. Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential

    Angiogenesis, Vol. 17, Núm. 3, pp. 603-616

2013

  1. PHD2 regulates arteriogenic macrophages through TIE2 signalling

    EMBO Molecular Medicine, Vol. 5, Núm. 6, pp. 843-857

2012

  1. Gene-Targeting of Phd2 Improves Tumor Response to Chemotherapy and Prevents Side-Toxicity

    Cancer Cell, Vol. 22, Núm. 2, pp. 263-277

2011

  1. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis

    Nature, Vol. 479, Núm. 7371, pp. 122-126

2010

  1. From vessel sprouting to normalization: Role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 30, Núm. 12, pp. 2331-2336

  2. Loss or Silencing of the PHD1 Prolyl Hydroxylase Protects Livers of Mice Against Ischemia/Reperfusion Injury

    Gastroenterology, Vol. 138, Núm. 3

  3. Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions

    Cardiovascular Research, Vol. 86, Núm. 1, pp. 29-36

2009

  1. Development of targeted angiogenic medicine

    Journal of Thrombosis and Haemostasis, Vol. 7, Núm. 1, pp. 21-33

2008

  1. Beneficial effects of prolonged systemic administration of PIGF on late outcome of post-ischaemic myocardial performance

    Journal of Pathology, Vol. 216, Núm. 2, pp. 236-244

  2. Genetics, epigenetics and pharmaco-(epi)genomics

    Journal of Cellular and Molecular Medicine, Vol. 12, Núm. 6B, pp. 2533-2551

2007

  1. Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice

    Journal of Clinical Investigation, Vol. 117, Núm. 11, pp. 3188-3197

1986

  1. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components

    Journal of Clinical Investigation, Vol. 78, Núm. 1, pp. 138-144

  2. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo

    The Journal of Laboratory and Clinical Medicine, Vol. 108, Núm. 1, pp. 44-52